Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-selenium as a radiotherapy sensitizer in small cell lung cancer
ChiCTR2600130406Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoselenium in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
nanoselenium
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600130406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130406.